Related Experiment Video
Updated: Sep 9, 2025

LERLIC-MS/MS for In-depth Characterization and Quantification of Glutamine and Asparagine Deamidation in Shotgun Proteomics
Published on: April 9, 2017
Profiling the landscape of cysteine posttranslational modifications in brain aging and neurodegeneration
1School of Molecular Biosciences, University of Glasgow, Glasgow, United Kingdom.
Abstract:
Cysteine residues occupy a unique position in the proteome: their thiolate side chain combines high nucleophilicity with redox sensitivity, making them prime targets for a diverse and ever-expanding array of post-translational modifications (PTMs). This review provides an overview of recent methodological developments for chemoselective site-specific detection and quantitation of the major cysteine PTMs-sulfenylation (RSOH), sulfinylation (RSO2H), sulfonylation (RSO3H), persulfidation (RSSH), S-nitrosylation (RSNO), and S-palmitoylation-emphasizing applications in brain aging and neurodegeneration. In neural tissues, these approaches have begun to map age-dependent increases in sulfenylation and sulfonylation, declines in persulfidation, and aberrant S-nitrosylation and palmitoylation linked to Alzheimer's, Parkinson's, and Huntington's disease. However, significant challenges remain. Further improvements in sensitivity, specificity, and quantitative accuracy are essential to capture low-abundance and labile modifications in complex neural tissues. These attempts should be coupled to more detailed anatomical dissection of these modifications in different parts of the brain, enabling region- and cell-type-specific insights. Advancing analytical workflows, integrating multi-dimensional data, and linking chemical modifications to biological outcomes will pave the way for innovative therapeutic strategies targeting cysteine chemistry in neurological disease.
More Related Videos
09:00Biochemical Purification and Proteomic Characterization of Amyloid Fibril Cores from the Brain
Published on: April 28, 2022
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016